Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic partnership with compatriot firm HuaDao Biopharma. Under the agreement, HuaDao will guide Boai NKY in establishing a GMP-aligned chimeric antigen receptor (CAR) T-cell therapy development incubator.
HuaDao has agreed to prioritize Boai NKY for the exclusive sales rights of its HD CD19 CAR-T drugs in the Shanxi, Henan, Hubei, and Hunan provinces, under the same conditions of exclusive sales rights and authorization fees. Additionally, Boai NKY will be given priority for marketing HuaDao’s anti-aging CAR-T products under the same licensing fees. Financial details of the partnership were not disclosed.
HuaDao’s HD CD19 CAR-T cell therapy received tacit clinical trial approval in China in August last year for the treatment of refractory or recurrent B-cell acute lymphoblastic leukemia.- Flcube.com
